Skip to main content
OpenTrials
Completed

NCT Number: NCT04995172

Feasibility of Mobile-CT-Assisted Bronchoscopy for the Diagnosis of Lung Lesion

This study investigates whether using a mobile-CT-assisted bronchoscopy (M-CAB) during a bronchoscopy procedure will better enable the study staff to reach the lung tumor, perform a biopsy, and obtain a diagnosis. One method that doctors use for diagnosing lung tumors is bronchoscopy guided by an X-ray machine (called fluoroscope). Though much better guidance could be provided with a CT scanner when compared to the fluoroscope, the standard CT equipment is very large, fixed in a radiology room, and difficult to use with bronchoscopy. Mobile CT imaging systems may more easily and effectively perform the same tasks of the standard CT imaging in the bronchoscopy room, offering better guidance than the standard fluoroscope.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Neoplasm Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

M D Anderson Cancer Center

Houston, Texas, 77030, United States

About this study

PRIMARY OBJECTIVE

I. To determine the added value of mobile-CT)-assisted bronchoscopy (M-CAB) for the diagnosis of peripheral lung nodules defined as the proportion of patients in whom bronchoscopy with radial-probe endobronchial ultrasound (RP-EBUS) and 2-D Fluoroscopy is non-diagnostic (lesion is not reached or rapid-onsite cytology is non-diagnostic) and diagnosis is obtained after utilizing mobile-CT assistance.

SECONDARY OBJECTIVES:

I. Describe the navigational yield of bronchoscopy with RP-EBUS/2-dimensional (2-D) fluoroscopy for peripheral nodules.

II. Describe the diagnostic yield of bronchoscopy with RP-EBUS/2-D fluoroscopy for peripheral nodules.

III. Describe the mobile-CT (M-CT) added navigational yield. IV. Describe the sensitivity for malignancy of bronchoscopy with RP-EBUS/2-D fluoroscopy and its increase (if any) provided by mobile-CT assistance.

V. Describe anatomical and procedural characteristics that can influence navigational and diagnostic yield (tumor location, tumor characteristics -solid, semisolid-, air-bronchus sign, biopsy tool, relationship between biopsy tool/tumor).

VI. Describe procedure duration. VII. Describe time required to obtain mobile CT scans VIII. Describe fluoroscopy time and estimate radiation dose to the patient. IX. Describe procedural complications.

OUTLINE:

Patients undergo RP-EBUS bronchoscopy per standard of care. If the study staff cannot reach the target lesion or is unable to determine a diagnosis, patients undergo bronchoscopy using mobile CT imaging. Patients' medical records are also reviewed for up to 6 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of 18 years of age or older undergoing bronchoscopy for diagnosis of a peripheral lung lesion from 1 to 3.5 cm in diameter located in the outer 2/3 of the lung fields

Exclusion criteria

  • Pregnant or breastfeeding women
  • Patients who cannot tolerate raising both arms above their head (position for obtaining mobile-CT images)
  • Patients with any contraindication for general anesthesia (e.g., severe and active coronary artery disease, chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) < 1 liter, uncontrolled hypertension, increased intracranial pressure, history of intolerance to general anesthesia)
  • Dementia or other severe cognitive impairment causing inability to understand or consent to the procedure and study

Treatment and study plan

Computed Tomography

Procedure

Undergo mobile CT-assisted bronchoscopy

Other names: CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography

Electronic Health Record Review

Other

Patients' medical records are reviewed

Endobronchial Ultrasound Bronchoscopy

Procedure

Undergo radial probe EBUS

Other names: EBUS, Endobronchial Ultrasound

Primary outcomes

  1. The added value of mobile-computed tomography (CT)-assisted bronchoscopy (M-CAB)

    Time frame: Up to 6 months

    Defined as the proportion of patients in whom bronchoscopy with thin or ultrathin scope, radial-probe endobronchial ultrasound (RP-EBUS) and 2-dimensional (2-D) fluoroscopy is non-diagnostic (lesion is not reached or rapid-onsite cytology is non-diagnostic) and diagnosis is obtained after utilizing mobile-CT assistance. Descriptive statistics (mean standard deviation [SD] or median interquartile range [IQR], frequency [%]) will be used to summarize patient characteristics.

Secondary outcomes

  1. Navigational yield of thin/ultrathin scope/RP-EBUS/2-D fluoroscopy for peripheral nodules

    Time frame: Up to 6 months

    Navigational yield for standard of care (SOC) will be estimated along with 95% confidence intervals (CIs).

  2. Diagnostic yield of thin/ultrathin scope/RP-EBUS/2-D fluoroscopy for peripheral nodules

    Time frame: Up to 6 months

    Diagnostic yield of SOC and diagnostic yield of SOC + M-CT along with their 95% CIs will be estimated.

  3. Mobile-CT (M-CT) added navigational yield

    Time frame: Up to 6 months

    M-CT added diagnostic yield in a subgroup with non-diagnostic subjects by SOC will be estimated along with its 95% CI. M-CT added diagnostic yield in a subgroup with non-diagnostic subjects by SOC will be estimated along with its 95% CI. Two-sided exact binomial test will be used to test if diagnostic yield of SOC + M-CT is significantly different from 0.2 in the subgroup.

  4. Sensitivity for malignancy of thin/ultrathin scope/RP-EBUS/2-D fluoroscopy and its increase (if any) provided by mobile-CT assistance

    Time frame: Up to 6 months

    Sensitivity for malignancy of SOC and sensitivity for malignancy of SOC + M-CT will be estimated, considering final pathology as the gold standard test.

  5. Anatomical and procedural characteristics that can influence navigational and diagnostic yield

    Time frame: Up to 6 months

    Anatomic and procedural characteristics that are associated with navigational and diagnostic yield will be evaluated by multivariate logistic regression models. A p-value of less than 0.05 will indicate a statistical significance.

  6. Procedure duration

    Time frame: Up to 6 months

    Will be summarized by mean (standard deviation [SD]) or median (interquartile range [IQR]).

  7. Time required to obtain mobile CT scans

    Time frame: Up to 6 months

    Will be summarized by mean (SD) or median (IQR).

  8. Fluoroscopy time

    Time frame: Up to 6 months

    Will be summarized by mean (SD) or median (IQR).

  9. Radiation dose to the patient

    Time frame: Up to 6 months

    Will be summarized by mean (SD) or median (IQR).

  10. Procedural complications

    Time frame: Up to 6 months

    Complications will be tabulated.

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Official study title

Mobile-CT-Assisted Bronchoscopy

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Aug 6, 2021
Registry last updated
Dec 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.